The U.S. dominates second-quarter global M&A as mega deals roll on The U.S. drugmaker AbbVie Inc $63 billion agreement to acquire peer Allergan PLC. This acquisition creates compelling value for Allergan’s stakeholders, including the customers, patients, and shareholders. With 2019 annual combined revenue of approximately $48 billion, scale in more than 175 countries, an industry-leading R&D pipeline and robust cash flows. The combined company will have the opportunity to make even bigger contributions to global health.
ABBVIE LONG (Buy)
Enter at: 70.37